Podcasts about saxenda

Os medicamentos injetáveis para emagrecimento, conhecidos como “canetas emagrecedoras”, incluindo Ozempic, Wegovy, Saxenda, Mounjaro e similares vinham sendo vendidos livremente no Brasil, sem a necessidade de prescrição médica. Mas isso vai mudar.A Agência Nacional de Vigilância Sanitária (Anvisa) aprovou uma nova regra para a venda desses medicamentos, que só poderá ser feita mediante apresentação de receita médica em duas vias, sendo que uma delas ficará retida na farmácia - procedimento semelhante ao já adotado para antibióticos.Neste episódio, conversamos sobre as indicações desses medicamentos, seus efeitos colaterais e a importância do acompanhamento médico para o uso correto.Links relacionados:Tirzepatide as Compared with Semaglutide for the Treatment of ObesityComida Sem Filtro #88 – Injetáveis Para EmagrecerComida Sem Filtro #146 – Ozempic: Como Evitar O Reganho De Peso?Comida Sem Filtro #125 – Efeito Ozempic Na Indústria De AlimentosEstamos no Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. Souto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sari Fontana⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Para ser avisado sobre cada novo episódio e receber os links das matérias mencionadas e as referências bibliográficas por e-mail, cadastre-se gratuitamente em ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drsouto.com.br/podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira seu livro - UMA DIETA ALÉM DA MODA: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (também na versão Kindle)"Dance of the Sugar Plum Fairy"Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 3.0⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://creativecommons.org/licenses/by/3.0/⁠

As famosas canetas emagrecedoras como Ozempic, Wegovy, Saxenda e similares agora serão vendidas com retenção da receita médica. A nova regra foi anunciada pela Anvisa, a Agência Nacional de Vigilância Sanitária, e entra em vigor em 60 dias. Atualmente, essas medicações são classificadas com a tarja vermelha. Ou seja, para comprar é preciso apresentar a receita. Mas, na prática, elas são vendidas sem receita e usadas sem acompanhamento médico, podendo causar inúmeros efeitos colaterais. No podcast de hoje, o endocrinologista João Eduardo Salles explica o porquê da decisão da Anvisa. E você também vai saber as novidades que estão chegando para o controle da obesidade e para ajudar quem quer perder peso. Tanto no mercado privado quanto no SUS.

Esta semana en esta porquería: en el Día Internacional de la Visibilidad Trans, Samango viene disociada (maybe she's having a stroke?) así que viene extra diver, Lilliana sintiendo los efectos secundarios de la Saxenda, queremos ponernos fillers y botox, pasó el Transitarte y OTRA VEZ NO FUIMOS, por enésima vez nos damos cuenta de que Tía Florita tiene 98 AÑOS, querer espacios child-free / adultocentrismo / tenerle paciencia a los carajillos, y ahí se acaba porque esta vez no hubo sección de la pamp.----------------------Suscríbanse a nuestro ⁠⁠canal de YouTube⁠ para cositas extra

En este episodio cortito con título turbo serio: acabamos de comer Rosti cortesía de Bebico Perdido, Samango viene enferma y despersonalizada, Joss viene hecha mierda por la Saxenda, y todo eso significa derangement y diversión, Rodrigo Chaves siendo un borracho pleitero y Pilar Cisneros siendo un pingüino, ropita de oficina, ya dejen de hacer GRWM si son viejas básicas u hombres (cualquier hombre), DEJEN DE CREERSE VIKINGOS, la Chilindrina siendo Sabrina Sabrok, por tercera vez nos damos cuenta de que Inés Sánchez de Revuelta se murió, y cerramos con una mini sección de la pampa.----------------------Suscríbanse a nuestro ⁠⁠canal de YouTube⁠ para cositas extra

A Agência Nacional de Vigilância Sanitária (Anvisa) decidiu que será obrigatória a retenção de receita médica para venda de medicamentos como Ozempic, Wegovy, Saxenda, Mounjaro e similares, que são usados para o emagrecimento. A decisão passará a ter valor em junho. Para o psicólogo e psicanalista especialista em grupos de compulsão alimentar, Paulo Buosi, a restrição da venda é importante para organizar o consumo e a orientação sobre as reações à medicação. Buosi ressalta que a procura das canetas injetáveis é feita por pessoas que buscam uma saída rápida para a obesidade, que afeta um em cada três brasileiros, segundo o Atlas da Obesidade 2025. "Uso sem receita de canetas para emagrecer pode levar à compulsão alimentar", alerta.See omnystudio.com/listener for privacy information.

Ok, chegou aquela hora, você se olha no espelho e precisa ser honesto consigo mesmo: você precisa emagrecer, você precisa buscar de volta sua vitalidade e precisa se sentir bem novamente com seu corpo.  É hora de mudar e isso é ótimo. A pergunta é: QUE RAIOS FAZER PRA ISSO? Que dieta, jejum, detox, exercício, cirurgia, injetáveis? Qual funciona melhor e qual piora tudo?  Vou te contar agora 7 formas muito populares de emagrecimento que na verdade são um tiro no pé e podem levar você a engordar mais ao invés, curioso pra saber?  ▶️Vídeos Recomendados:  -O Que Acontece No Corpo Quando Você Corta Carboidratos  https://www.youtube.com/watch?v=7jN_zPDqAqg  -OZEMPIC - Os Fatos Por Trás Das Promessas (Mounjaro, Saxenda, etc.)  https://www.youtube.com/watch?v=C_ICPKk3BcQ

As we work our way through the alphabet from A to Z in my drug pronunciation series, we're on the letter “L.” Disclaimer: we don't cover pharmacology in this series. Just drug names.   In this episode, I'll divide liraglutide, Victoza, and Saxenda into syllables, tell you which syllables to emphasize, and share my sources. Written pronunciations are helpful, so you'll find all three below and in the show notes for episode 324 on thepharmacistsvoice.com. Once you've listened to this episode, practice saying liraglutide, Victoza, and Saxenda. Repetition is the key to mastery.   Thank you for listening to episode 324 of The Pharmacist's Voice ® Podcast. The FULL show notes (including all links) are on https://www.thepharmacistsvoice.com/podcast.  Select episode 324.   Liraglutide = LIR a GLOO tide  LIR, like a Learjet Uh, which is a short “A” sound or a schwa “A” sound.  GLOO, like the sticky substance we use to stick two things together And tide, like the ocean tide Sources: Novo Nordisk Customer Service, MedlinePlus, and drugs.com    Victoza = VIC-tow-za  VIC, like Victor Tow, like a tow truck And za, like pizza Emphasize VIC Sources: Novo Nordisk Customer Service, drugs.com, and the FDA's website    Saxenda = sax en duh Sax, like a saxophone En, like the letter “N” in the alphabet Duh, which is an interjection we use in the US to mean, “Isn't it obvious?!” For example, if someone told you, “Water is wet,” you might say, “Duh! Water IS wet.”

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________Streamed live on Mar 26, 2025261 views • Streamed live on Mar 26, 2025Unlike traditional media, our live sessions offer raw, real-time discussions on obesity treatments. The community can engage directly in the comments, share their perspectives, and connect with experts and fellow patients. It's a space for honest dialogue, advocacy, and breaking the stigma around obesity, all while staying informed about the latest breakthroughs and understanding Mounjaro, Zepbound, Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza and all the newest GLP1s.______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Sorry, you can only get drugs when there's a drug shortage. Three GLP-1 drugs are approved for weight loss in the United States: Semaglutide (Ozempic®, Wegovy®, Rybelsus®) Tirzepatide (Mounjaro®, Zepbound®) Liraglutide (Victoza®, Saxenda®) …but liraglutide is noticeably worse than the others, and most people prefer either semaglutide or tirzepatide. These cost about $1000/month and are rarely covered by insurance, putting them out of reach for most Americans. …if you buy them from the pharma companies, like a chump. For the past three years, there's been a shortage of these drugs. FDA regulations say that during a shortage, it's semi-legal for compounding pharmacies to provide medications without getting the patent-holders' permission. In practice, that means they get cheap peptides from China, do some minimal safety testing in house, and sell them online. So for the past three years, telehealth startups working with compounding pharmacies have sold these drugs for about $200/month. Over two million Americans have made use of this loophole to get weight loss drugs for cheap. But there was always a looming question - what happens when the shortage ends? Many people have to stay on GLP-1 drugs permanently, or else they risk regaining their lost weight. But many can't afford $1000/month. What happens to them? Now we'll find out. At the end of last year, the FDA declared the shortage over. The compounding pharmacies appealed the decision, but last month the FDA confirmed its decision was final. As of March 19 (for tirzepatide) and April 22 (for semaglutide), compounding pharmacies will no longer be able to sell cheap GLP-1 drugs. Let's take a second to think of the real victims here: telehealth company stockholders. https://www.astralcodexten.com/p/the-ozempocalypse-is-nigh

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Sign The Petition for Avoidable Access to GLP-1s https://glp1collective.org/ ______________________________________________________________________We discuss Wegovy, Ozempic, Mounjaro, Zepbound, Rybelsus, Saxenda, and Victoza and the active ingredients Tirzepatide and Semaglutide. Unlike traditional media, our live sessions offer raw, real-time discussions on obesity treatments, where the community can engage directly in the comments, share their perspectives, and connect with experts and fellow patients. It's a space for honest dialogue, advocacy, and breaking the stigma around obesity, all while staying informed about the latest breakthroughs. Tonight, we are joined by @Downsidezed    / @thedownsized  ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF_____________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Barrie hates when people refer to St. Patrick's Day as St. Paddy's Day. Anne remembers poet and raconteur, Pat Ingoldsby. Stephen says antisocial behaviour has gone out of control on Moore Street. Laura Ruth believes foxes are misunderstood. Callers describe their experiences of using Ozempic and Saxenda.

Send us a textDive into a conversation that brims with the hilarity and struggles of everyday life as we navigate our personal health journeys. We touch upon the wild chaos that often accompanies change—think of cats misbehaving and unexpected deep thoughts, all while reflecting on our experiences with GLP-1 medications like Ozempic and Saxenda.Our discussions take us through the ups and downs of forming healthier habits, shifting from binge eating patterns, and learning to re-establish a balanced relationship with food in light of our changing appetites. Both of us find ourselves at a crossroads, contemplating new personal goals and strategies intended to forge a more robust commitment to our well-being. Throughout the episode, we emphasize the importance of kindness—a reminder that every journey is personal, and we must treat ourselves with compassion as we navigate through layers of emotions. By sharing our challenges, setbacks, and fleeting victories, we encourage listeners to reassess their paths, explore their motivations, and take proactive steps toward their goals.Join us for this insightful, humorous, and deeply relatable episode as we strive to find balance and embrace our authentic selves. We can't wait to hear your thoughts and experiences—don't hesitate to share and connect with us!Support the showDo you have a story you would like to share? Send it to us at theweightingroompc@gmail.comDisclaimer: We are not Medical professionals and all views and opinions are our own.

Hoy en día podemos ver en los medios de comunicación como famosos de la talla de Elon Musk, Oprah Winfrey, Cristina aguilera, Kim kardashian, Luis Miguel, Lady Gaga y decenas de actrices de Hollywood, o ricos de Sillicon Valley… comentan que han perdido mucho peso y sin esfuerzo, gracias a un medicamento Unos hablan de ozempic, otros de wegoby y otros de mounjaro…. Otros comentan sus principios activos, liraglutida, semaglutida o tirzepatida Pero prácticamente nadie se ha parado a explicar los razonamientos fisiológicos que hay detrás de todo esto… Y para ello os traigo a Alfredo Andreu, farmacéutico , nutricionista y autor del libro, Ozempic & Co: Apagando el Ruido de la Comida, Perdiendo Peso y este es su web: https://www.habitonutricion.com/ Hablaremos de: Que es impacto tienen la insulina y el glucagón en la perdida de grasa y sensación de hambre y saciedad Que es el GLP 1 y que son los análogos de GLP 1 ) agonista del receptor del péptido similar al glucagón tipo 1 (GLP-1): Acciones en cerebro; hipotálamo nervio vago / pancreas: aumenta insulina y baja glucagón / tracto gastrointestinal vaciamiento gastrico tipos de medicamentos Agonistas duales GLP-1/GIP) Novo Nordisk: Produce Ozempic, Wegovy, Rybelsus, Victoza y Saxenda. Eli-Lilly: Trulicity y Mounjaro., Mounjaro es el primer agonista dual de GLP-1 y GIP, con potencial superior en la pérdida de pes Elimina grasa vs perder apetito…. Musculo y hueso Mi comparación : sueño y descanso ---- esteroides Efectos secundarios corto plazo (estomacales, Reducción de acetilcolina, lo que puede afectar la motilidad intestinal y la contracción muscular, hipoglucemias) medio plazo (posibilidad pancreatitis, cancer de tiroides…) largo plazo (rebote, perdida de masa muscular) Realmente quien debería ser candidato… ultima bala antes de operación en obesidad mórbida? Recuerda su web: https://www.habitonutricion.com/

In this episode of the Movement Prescription Podcast, Callum sits down with GP and lifestyle medicine experts Hussain and Suzy to explore the transformative role of GLP-1 agonists in obesity management. They discuss how medications like Saxenda and Wegovy work to modulate hunger and satiety, and emphasize the importance of pairing these treatments with lifestyle changes—especially regular physical activity—to achieve sustainable weight loss. The conversation also delves into potential side effects, the benefits of preserving muscle mass through resistance training, and the broader challenges faced within the NHS. Tune in for evidence-based insights and actionable strategies for integrating pharmacological and lifestyle interventions in the fight against obesity.Produced with support from the British Society of Lifestyle Medicine.Find us at https://themovementprescription.co.uk/ and join the conversation!

Dit is deel 2 van het gesprek met dr Tom Schilder over afvalmedicatie.Tom is arts en medisch adviseur bij stichting Je Leefstijl als Medicijn. Tijdens zijn studie raakte hij gefascineerd door chronische ziektes en het ontstaan daarvan. Dat kwam omdat hij tijdens zijn co-schappen merkte dat het meeste ziekteleed van chronische ziektes kwam. Het viel hem op dat het meerendeel van de behandelingen gericht zijn op de symptomen terwijl de oorzaak van de chronische ziektes niet wordt aangepakt.In deze aflevering hebben we het over:- Afvalmedicatie: wat zijn GLP-1 agonisten?- Verschil tussen Ozempic, Saxenda en Mounjaro- Gevaar van afvalmedicatie / GLP-1 agonisten- Leefstijl en afvalmedicatie / GLP-1 agonisten- Landbouw en microbioom- Tom zijn project: een ZorgboerderijContact Tom Schilder via tom@jeleefstijlalsmedicijn.nl

n this episode of Fat Science, Dr. Emily Cooper, Andrea Taylor and Mark Wright explore cravings and the role they play in metabolic dysfunction. If you watch some drug company commercials these days, you'd think cravings are the culprit for obesity. In reality, they are just a symptom of a deeper metabolic problem.  This episode of Fat Science uncovers why this oversimplification is not just misleading but harmful to those struggling with metabolic dysfunction.  Join us as we explore the science behind cravings, debunk common myths and highlight the importance of understanding your metabolic health. Key Takeaways: Not Just an Overeating Problem: Learn why targeting cravings alone is not the answer to managing weight and metabolic health. Metabolic Dysfunction Explained: Discover how metabolic dysfunction manifests in various forms, such as irregular appetite signals, and why addressing the root cause is crucial for effective treatment. The Role of Medications: Dr. Cooper breaks down commonly-prescribed medications like Contrave, Qsymia, and Saxenda—explaining their true function in strengthening metabolic pathways rather than merely suppressing cravings. Misleading Advertising: Understand the detrimental effects of current advertising campaigns that focus on willpower and cravings and how they perpetuate weight stigma and misinformation.   Resources: Connect with Dr. Emily Cooper on LinkedIn. Connect with Mark Wright on LinkedIn. Connect with Andrea Taylor on Instagram. Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice. If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org. Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

In this enlightening episode of Healthy AF, Amy dives into the comprehensive world of GLP-1 RA drugs and their impact on weight loss. Whether you're contemplating starting a GLP-1 RA regimen or already on one and seeking more insight, this episode is packed with all the good information you need. Amy covers everything from the basics of GLP-1 RA drugs to the latest updates and data up to 2024. Discover practical advice on what additional health measures you can take while on these drugs to mitigate adverse effects and sustain weight loss. Tune in to arm yourself with knowledge and make informed decisions about your health journey with GLP-1 RA drugs. Trying to get healthy and stay healthy is f-ing hard! Everybody struggles with some aspect of it, no matter what they look like or what they tell you. There is no magic formula - a healthy lifestyle is a choice we need to make daily. Join Amy as she supports, informs, and entertains you on your journey toward health.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, we're tackling a question I've been hearing a lot: What happens if you want to stop your GLP-1 medication (like Ozempic, Wegovy, Mounjaro, Zepbound, or Saxenda)? Whether you're making this decision voluntarily or because circumstances force it, I'll walk you through evidence-based strategies to minimize weight regain and ensure the best outcomes. Here's what I'll cover today: What happens when you stop GLP-1 medications? GLP-1s are not just weight loss tools; they treat a chronic disease—obesity. Weight regain after stopping is common and tied to metabolic and hormonal adaptations. What research tells us about this transition: The STEP-1 Extension Trial showed patients regained about two-thirds of the weight they lost after stopping semaglutide, even with lifestyle interventions. A Diabetes, Obesity and Metabolism study highlights that weight regain is a natural metabolic response, not a failure of willpower. Why long-term GLP-1 use is often recommended: Think of GLP-1s like treatment for other chronic diseases, such as diabetes or hypertension. For most people, ongoing therapy is necessary for sustained benefits. Evidence-based strategies for transitioning off GLP-1s: Gradual tapering: Slowly reduce your dose under medical supervision. Focus on nutrition: Increase protein intake and monitor your eating habits closely. Prioritize physical activity: Incorporate resistance training to preserve muscle and support your metabolism. Use psychological tools: Employ CBT or other techniques to handle emotional eating and cravings. Consider adjunct therapies: Discuss options like metformin with your doctor. Key takeaway: Transitioning off GLP-1s is not one-size-fits-all. It requires close collaboration with your healthcare provider, a strong emphasis on lifestyle habits, and ongoing psychological support. Whatever path you choose, remember this journey is about long-term health, not just weight loss.

In this episode of Fat Science, Dr. Emily Cooper, Andrea Taylor and Mark Wright take a comprehensive look at the current FDA-approved medications designed to treat metabolic dysfunction and what may be approved next.  Dr. Cooper discusses the range of factors that determine whether these essential drugs are available for those who need them. Government approval, drug company strategies and insurance company policies all play a role.  Key Takeaways: Pharmaceutical Approval Process: Pharmaceutical companies typically seek FDA approval for one drug indication at a time due to the high costs and extensive trial requirements. Approval for obesity drugs is more stringent than for diabetes, involving costly and rigorous trials. Rebranding Drugs for Accessibility: Drugs like Liraglutide (originally Victoza for diabetes) are rebranded as Saxenda for obesity to bypass insurance coverage issues. However, rebranding can create coverage gaps for weight-loss purposes, leaving some patients without access. Insurance Coverage Challenges: Insurance companies often limit coverage for these medications unless a patient has a diagnosed condition like type 2 diabetes. Preventative benefits of metabolic medications are frequently overlooked by insurers, limiting broader access. Risks with Compounded Medications: Compounding pharmacies are creating untested versions of GLP-1 drugs to address affordability and shortages, raising safety concerns. Future Developments in Metabolic Meds: New potential drugs, such as a dual hormone agonist and high-dose semaglutide as a daily pill, show promise in improving metabolic health and accessibility. Resources: Connect with Dr. Emily Cooper on LinkedIn. Connect with Mark Wright on LinkedIn. Connect with Andrea Taylor on Instagram. Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice. If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org. Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

No hay duda de que vivimos en la era Ozempic. Nació para combatir la diabetes tipo 2, pero ha revolucionado la lucha contra la epidemia de la obesidad. En Estados Unidos, donde está más extendido, se ha frenado por primera vez en más de una década. Son dos hechos que coinciden, por lo menos, en el tiempo. La cuestión es que puede que estemos ante una nueva era, gracias a esta familia de medicamentos, que va mucho más allá de la pérdida de peso. Alzhéimer, párkinson, adicciones a alcohol y drogas, ¿una nueva revolución? Lo analizamos con Pilar Pérez, jefa de Salud de EL MUNDO  See omnystudio.com/listener for privacy information.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: World Diabetes Day roundup, existing drugs examined for T1D prevention, Blue Circle Health expands its novel T1D care model, Mounjaro studied further, Canada approves a new pumps system, and tragedy in the diabetes community.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Of course, World Diabetes Day was yesterday. November 14 marks the birthday of Sir Frederick Banting. who discovered insulin along with Charles Best in 1922. Lots of the tech companies are taking action.. I'm going to link up a great article highlighting what many of them are doing…. from Medtronics Blue Balloon challenge to Dexcom's Nick Jonas video and a lot more. https://www.drugdeliverybusiness.com/world-diabetes-day-2024/ XX A new triple combo therapy could restore insulin production in people with type 1 using existing medications. Levicure's triple-combo oral therapy is already considered very safe, because it involves two drugs approved by the U.S. Food and Drug Administration (FDA) and a well-known supplement. The therapy is a combination of: DPP4-inhibitors, a common type 2 diabetes medication Proton pump inhibitors (PPIs), a drug for severe acid reflux A proprietary version of gamma-aminobutyric acid (GABA), a supplement often used to treat anxiety Levicure says the combined effect can block beta cell destruction, suppress autoimmunity, and restore beta cell function. So far, Levicure's triple therapy has gone through only one retrospective chart review; it has not been put to the test in a randomized controlled trial https://www.diabetesdaily.com/blog/can-this-triple-combo-oral-therapy-restore-insulin-production-733261/   XX Blue Circle Health is expanding it's unique approach to type 1 care. Already active in Florida, Maine & Vermont, it will now be in Delaware and Ohio. Blue Circle Health is free and develops a personalized care plan for each participant, tailored to their unique needs, and offers comprehensive multidisciplinary support over a six-month period. It's paid for by the Helmsley Charitable Trust. The program is available to people 18 years of age and older that speak Spanish or English, regardless of insurance coverage or citizen status. We've got an upcoming podcast episode all about Blue Circle coming up soon. https://www.prnewswire.com/news-releases/blue-circle-health-expands-to-delaware-and-ohio-to-address-health-system-barriers-to-type-1-diabetes-care-and-education-302304170.html XX An international team of experts has created the world's first evidence-based guide for eating lower and low carb. The group says until now, people with type 1 diabetes and their healthcare providers have lacked comprehensive resources to help implement this approach safely and effectively. The guide provides essential information for dietitians and nutritionists and empowers them to work collaboratively with individuals and families who are interested in reducing carbohydrates. It's free and we've got the download link in the show notes. https://www.newswire.ca/news-releases/international-team-launches-first-guide-for-carbohydrate-reduction-in-type-1-diabetes-883729104.html XX A new pump system is available in Canada. mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. mylife Loop consists of the mylife YpsoPump, a lightweight intuitive insulin pump, integrated with the CamAPS FX hybrid closed-loop, a mobile phone-based algorithm, and the Dexcom G6 Continuous Glucose Monitoring (CGM) System. Working together, these components provide an innovative, automated insulin delivery (AID) system designed to simplify insulin therapy and improve glycemic control for Canadians living with diabetes.   "The approval of the mylife YpsoPump and CamAPS FX marks an important milestone as we bring these advanced technologies to the Canadian market," said Sébastien Delarive, Chief Business Officer of Ypsomed Diabetes Care. "Although Ypsomed is relatively new in Canada, our established leadership in diabetes care throughout Europe provides a solid foundation for delivering innovative solutions to Canadians living with type 1 diabetes."   "We are excited to see both mylife YpsoPump and CamAPS FX approved," said Karina Schneider, General Manager at Ypsomed Canada. "This step brings us closer to offering an integrated solution that will help simplify diabetes management for Canadian patients, empowering them to take more control of their health." https://finance.yahoo.com/news/ypsomed-camdiab-receive-health-canada-205500840.html XX The FDA updates the labels for all GLP-1 receptor agonists with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). the Medication Guide section of the label also has new additions. Patients are counseled to tell their healthcare provider if they are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). They are alerted that the GLP-1 RAs they are taking may cause serious side effects, including food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sedation. Patients are advised to tell all their healthcare providers that they are taking a GLP-1 RA before they are scheduled to have surgery or other procedures. https://www.medscape.com/viewarticle/fda-updates-glp-1-label-pulmonary-aspiration-warning-2024a1000k84?form=fpf XX Following an impressive data drop this summer highlighting the potential for Eli Lilly's tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drugmaker is laying out full results from its longest completed study of the dual GIP/GLP-1 receptor agonist to date. In the three-year SURMOUNT-1 trial, tirzepatide curbed the risk of disease progression to Type 2 diabetes by 94% versus placebo in adult prediabetes patients who were obese or overweight, Lilly said in a release Wednesday. The number represents a pooled result from three tirzepatide doses (5 mg, 10 mg and 15 mg) studied in the trial.   Putting those results into perspective, one new case of diabetes could be prevented for every nine patients treated with tirzepatide, which is marketed in the U.S. as Mounjaro for Type 2 diabetes and as Zepbound for obesity, Lilly said. https://www.fiercepharma.com/pharma/lilly-unwraps-detailed-data-showing-tirzepatide-kept-nearly-99-pre-diabetic-patients XX Edgparke commeical? XX https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions XX XX And finally, many of you have likely already heard but we had some incredibly tragic news in the diabetes community, especially for the Breakthrough T1D ride community. I'm going to read from the Breakthrough T1D website: The leadership, staff, and volunteers of Breakthrough T1D mourn the tragic, sudden loss of five T1D Champions on Friday, Nov. 1, 2024.  Jeff and Michelle Bauer, Josh and Tammy Stahl and Barry Sievers were all killed in a singe car crash. The group included two married couples and one single individual—all very close friends and veteran Breakthrough T1D Ride participants. Of this incredibly impactful group, I knew Michelle Bauer personally, I met her as Michelle Alswager – you may know her as Jesse's mom. Her son, Jesse died from complications of type 1 in 2010. And that year, mile 23 on the JDRF ride was created as a mile of silence in memory of Jesse.  Now all riders are asked to ride in silence for that mile not only in memory of Jesse, but all those lost to type 1 diabetes. Michelle wrote her book, Jesse Was Here and created a program that's part of Beyond Type 1 to this day, all to help other families going through grief. She called me a few years ago when she was thinking of writing her book and I'm so grateful for our conversations and that our conversations may have helped her get it out there into a world where it's so needed. But we need Michelle here to talk about grief. More about talking to Michelle about the book).   Please, write the book, ride the bike, do the ironman, follow your heart and your dreams.  All of these incredible people gone too soon. https://www.breakthrought1d.org/news-and-updates/breakthrough-t1d-mourns-tragic-sudden-loss-of-five-ride-champions/   Thanks for joining me..

Send us a textResources for the Community:____________________________________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55____________________________________________________________________________________________The Provider Spotlight is a new bonus series of shorter episodes featuring doctors and specialists from past sessions—think of it as 'doctor shorts.' With over 25k scripts for Zepbound written weekly, many new subscribers haven't seen our earlier episodes, which helps them catch up quickly. Thanks for your support!On August 8th 2023 Dr Sasha High set down with The Plus Sidez and discussed how mindset and obesity medical treatments such as Ozempic, Wegovy, Saxenda, Victoza, and Mounjaro.Dr. Sasha HighTikTok: @sashahighmdWebsite: https://www.sashahighmd.com/____________________________________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF____________________________________________________________________________________________Join this channel to get access to perks:   / @theplussidez____________________________________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

No podcast ‘Notícia No Seu Tempo', confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo' desta quinta-feira (24/10/2024): Empresas farmacêuticas e fabricantes de medicamentos de referência e de genéricos travam uma disputa acirrada na Justiça em torno de patentes de 62 medicamentos – entre eles, o Saxenda, de controle da diabetes e rival do Ozempic em tratamentos para perda de peso, e o Stelara, para doenças autoimunes. As donas das fórmulas originais querem manter a extensão do prazo de vendas exclusivas de seus remédios para além dos 20 anos legais de proteção das patentes. Mas uma mudança de entendimento do Supremo Tribunal Federal (STF), de 2021, é um empecilho para isso. A briga entre esses dois grupos começou a esquentar no contexto da pandemia de covid-19, quando ganhou força entre governos e políticos a ideia de acelerar e baratear tratamentos médicos.  E mais: Política: Estabilidade de Nunes em pesquisas já leva PT e PL a tentar atrair MDB Metrópole: CAC com esquizofrenia mata irmão, pai e PM e fere 9 em Novo Hamburgo Internacional: Brics aprova adesão de 13 países, sem Venezuela, apesar da visita de Maduro Caderno 2: Antonio Cicero: Poeta viveu em diálogo com a filosofia e a música  See omnystudio.com/listener for privacy information.

Send us a textToday, we're going to explore an exciting and increasingly popular area of weight loss treatment: GLP-1 receptor agonists. You may have heard of them through the names of medications like Saxenda, Ozempic or Wegovy. These medications are gaining a lot of attention for their potential to help people lose weight effectively, but like anything in medicine, they come with both pros and cons.Thanks for listening, I hope this episode will be helpful.Philippe

Man, I've been waiting for a long time for someone in Congress to say it this way. Maybe it's because I see it this way and I want them to be like me. You will hear Representative Thomas Massie, talking about how he doesn't want to be an actor in a kabuki theater. Zach Abraham and I are going to talk about this. It's one of the greatest speeches I think in the history of Congress. And what about crony capitalism unconstrained by any form of morality? Episode Links:Presidential debate live updates: Trump's call for government shutdown sharpens policy contrast with HarrisIs this the greatest political speech in the history of Congress?Inflation Expectations Rise Over Medium-Term As Delinquency Fears Unexpectedly Hit 4 Year HighWeight-loss drug Saxenda effective for kids as young as 6, study showsAlan's Soaps https://www.alansartisansoaps.com/Use coupon code ‘TODD' to save an additional 10% off the bundle price.Bioptimizers https://bioptimizers.com/toddStart your journey to better health with MassZymes.  Visit bioptimizers.com/todd today to get your MassZymes 10% off.  Bonefrog https://bonefrogcoffee.com/toddMake Bonefrog Cold Brew at home!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.Bulwark Capital Bulwark Capital Management (bulwarkcapitalmgmt.com)Learn about Bulwark's strategies with their FREE Common Cents Investing Guide.  Get yours by calling 866-779-RISK or go to KnowYourRiskRadio.com.EdenPURE https://edenpuredeals.comUse code TODD3 to save $200 on the Thunderstorm Air Purifier 3-pack.  Renue Healthcare https://renue.healthcare/toddYour journey to a better life starts at Renue Healthcare. Visit renue.healthcare/Todd

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. This week's commercialization news includes Dupixent's success in a chronic hives study, Lilly's development of a weekly insulin shot, and BioMarin's plans for growth. The House backs a bill restricting China's role in US biotech, while Lykos CEO is set to depart after FDA rejection and layoffs. The newsletter also discusses key developments in cell therapy and offers insights on utilizing a direct-to-patient model in the healthcare industry. Various resources and upcoming events in the biopharma industry are also highlighted. Biopharma Dive provides in-depth journalism and insights into the latest news and trends shaping the biotech and pharma industries.BridgeBio has reduced its gene therapy budget after data from a trial on an adrenal gland medicine did not meet the company's investment threshold. GlaxoSmithKline has discontinued a herpes vaccine after it did not meet efficacy goals in a phase 2 study. Roivant has launched a new 'vant' focused on a hypertension drug. Centessa's sleepiness drug has shown promising results in early studies, leading to a rise in the company's shares. Additionally, Dupixent has succeeded in a chronic hives study, giving Sanofi and Regeneron a chance to resubmit their application for approval. Investors are also paying attention to Centessa's sleepiness drug. This news comes alongside updates on other pharmaceutical developments, such as Saxenda's effectiveness for children as young as 6 and Roche's expansion of R&D labs. Additionally, the newsletter covers upcoming events and resources for biopharma professionals. Biopharma Dive provides in-depth coverage of news and trends in the biotech and pharma industries, including clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.Iowa has awarded Centene's subsidiary, Iowa Total Care, a Medicaid managed care contract worth $2.8 billion. Telehealth groups are urging Congress and the White House to extend controlled substance virtual prescribing before pandemic-era flexibilities expire. The Biden administration has finalized a rule raising mental health coverage standards for private plans. Steward Health Care received court approval to sell its three most valuable hospitals to Orlando Health for $439 million. The importance of data quality in realizing value from medical imaging data is emphasized by Enlitic. Payers are encouraged to optimize quality and grow revenue through key strategies in an upcoming webinar. Healthcare Dive provides in-depth journalism and insight into the most impactful news and trends shaping healthcare across various sectors like health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care.Novo Nordisk showcased its investigational GLP-1 pill that resulted in a remarkable 13% weight loss. This comes after positive Phase I results for the pill, which analysts compared to weight loss pills being developed by Lilly and Pfizer. Expanded coverage for cardiovascular disease under Medicare could have significant implications for Novo's obesity drug, Wegovy. Analysts estimate that the expansion of Wegovy's label beyond obesity could lead to an annual Medicare spending of $145 billion. Meanwhile, GSK has abandoned the development of its herpes vaccine after disappointing Phase I/II results, and Crispr Therapeutics and Vertex Pharmaceuticals are facing challenges in making their sickle cell gene therapy profitable. Novo's other drug, Saxenda, was found to effectively and safely lower BMI in children, according to a study published in NEJM. Additionally, Lilly continues to make progress with its once-weekly insulin, while Bain has raised $3 billion for a fund supporting life sciences companies. The biopharmaceutical industry continues to see changes, with Biomarin facing challenges and Terns moving forward in the obesity spac

¿Conoces los nuevos fármacos para el tratamiento de la obesidad? ¿Sabes que algunos de ellos tienen ya bastantes años? ¿Sabes como funcionan? ¿Pueden tener efectos secundarios? ¿Es suficiente con los fármacos o tengo que hacer algo más para perder peso? Si quieres saber más, no te pierdas este episodio de hoy con la Dra Laura Bartolomé.

Los medicamentos como Saxenda y Ozempic son análogos de GLP-1 (glucagón-like péptido-1) utilizados principalmente para el manejo de la diabetes tipo 2 y, en algunos casos, para el control de peso. Aquí tienes un resumen detallado sobre estos medicamentos:GLP-1 y su Mecanismo de AcciónGLP-1 es una incretina, una hormona que se libera en el intestino en respuesta a la ingesta de alimentos. Tiene varios efectos que ayudan a regular el azúcar en la sangre y el apetito:Estimulación de la secreción de insulina: Aumenta la liberación de insulina por el páncreas en respuesta a la comida.Inhibición de la liberación de glucagón: Disminuye la secreción de glucagón, una hormona que aumenta los niveles de glucosa en sangre.Retraso del vaciado gástrico: Ralentiza el vaciado del estómago, lo que ayuda a controlar el apetito y puede contribuir a la pérdida de peso.Reducción del apetito: Actúa sobre el cerebro para disminuir la sensación de hambre.Saxenda (Liraglutida)Uso:Aprobado para la pérdida de peso en adultos con un índice de masa corporal (IMC) de 30 o más (obesidad) o con un IMC de 27 o más (sobrepeso) y al menos una condición relacionada con el peso (como diabetes tipo 2, hipertensión o colesterol alto).Se utiliza en conjunto con una dieta reducida en calorías y un aumento de la actividad física.Administración:Inyección subcutánea diaria.Efectos Secundarios:Náuseas, vómitos, diarrea, estreñimiento.Dolor abdominal.Aumento de la frecuencia cardíaca.Posible riesgo de pancreatitis.Reacciones en el sitio de inyección.Precauciones:No se recomienda en personas con antecedentes de cáncer medular de tiroides o síndrome de neoplasia endocrina múltiple tipo 2.Debe ser usado con precaución en personas con antecedentes de pancreatitis.Ozempic (Semaglutida)Uso:Aprobado para el tratamiento de la diabetes tipo 2 para mejorar el control de la glucosa en sangre.También puede ser utilizado para la pérdida de peso en personas con obesidad o sobrepeso similar a Saxenda.Administración:Inyección subcutánea semanal.Efectos Secundarios:Náuseas, vómitos, diarrea, estreñimiento.Dolor abdominal.Posible riesgo de pancreatitis.Retinopatía diabética (en pacientes con diabetes tipo 2).Reacciones en el sitio de inyección.Precauciones:Similar a Saxenda, no se recomienda en personas con antecedentes de cáncer medular de tiroides o síndrome de neoplasia endocrina múltiple tipo 2.Debe ser usado con precaución en personas con antecedentes de pancreatitis.Otros Análogos de GLP-1Trulicity (Dulaglutida):Inyección subcutánea semanal.Usado para el manejo de la diabetes tipo 2.Similar perfil de efectos secundarios y precauciones.Victoza (Liraglutida):Misma sustancia activa que Saxenda, pero en dosis diferente.Aprobado para el manejo de la diabetes tipo 2.Bydureon (Exenatida de liberación prolongada):Inyección subcutánea semanal.Usado para el manejo de la diabetes tipo 2.Similar perfil de efectos secundarios y precauciones.Consideraciones GeneralesEficacia: Estos medicamentos han demostrado ser efectivos tanto para el manejo de la glucosa en sangre como para la pérdida de peso.Seguimiento Médico: Es crucial un seguimiento médico regular para monitorear la eficacia y los posibles efectos secundarios.Estilo de Vida: Deben ser utilizados en combinación con cambios en el estilo de vida, como una dieta saludable y ejercicio regular.Contraindicaciones: Se deben evitar en personas con antecedentes específicos de cáncer o pancreatitis y ser usados con precaución en personas con ciertas condiciones médicas.Estos medicamentos representan un avance significativo en el manejo de la diabetes tipo 2 y la obesidad, ofreciendo una opción adicional para los pacientes que no han respondido adecuadamente a otros tratamientos.Conviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/comiendo-con-maria-nutricion--2497272/support.

Saxenda善纖達（瘦瘦針）的減重原因就是讓人「減少進食量」，若想購買～建議務必透過專科醫師，先進行個人諮詢確認自身狀況，同步進行飲食內容調整、運動習慣養成等生活型態改變！ 飲食、運動歡迎問我

In February 2023, The Quicky published its first investigation into the rising popularity of weight loss drugs. News coverage of popular brands like Ozempic and Mounjaro has ranged from praise for its weight loss results, to concern over side effects, and even speculation about which celebrities were using them.  Eighteen months on, where does public perception of these drugs sit now?  THE END BITS  Subscribe to Mamamia Listen to more episodes about Ozempic here & here Check out our episode about Ozempic babies here Read more about Ozempic face here GET IN TOUCH Share your story, feedback, or dilemma! Send us a voice note or email us at podcast@mamamia.com.au and one of our Podcast Producers will come back to you ASAP. CONTACT US Got a topic you'd like us to cover? Send us an email at thequicky@mamamia.com.au CREDITS Host: Claire Murphy  With thanks to:  Dr Brad McKay, GP, Author, Podcast Host and Medical Commentator Producer: Claire Murphy  Senior Producer: Taylah StranoAudio Producer: Thom LionBecome a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Send us a Text Message.Ozempic reduces cancer risk:https://www.bloomberg.com/news/articles/2024-07-05/ozempic-may-lower-risk-of-obesity-related-cancers-study-findsSemaglutide correlated with blindness (tiktok video):https://www.statnews.com/2024/07/03/ozempic-wegovy-naion-vision-loss-study15-years as type-2 diabetic results in a 78% chance of have some degree of retinal eye damagehttps://www.webmd.com/diabetes/closer-look-diabetic-retinopathyUpdate to Mounjaro/ZepBound FDA shortage on 7/2/2024 (tiktok video)#releasethevialshttps://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide%20Injection&st=cMounjaro KwikPen coming to AustraliaNews provided by Mimi from Australia (Mimi featured in Live #61 -- part of Retatrutide trialsGIP scientific study:https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16478semaglutide vs. tirzepatide https://www.nbcnews.com/health/health-news/zepbound-outperforms-ozempic-wegovy-head-head-weight-loss-study-rcna160630Keto diet:https://www.biorxiv.org/content/10.1101/2024.06.14.599117v1High-price of GLP-1 medications:https://www.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007/?tbref=hpSupport the Show.MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/joinSOCIAL LINKShttps://www.tiktok.com/@manonthemounjarohttps://twitter.com/ManOnMounjarohttps://instagram.com/manonthemounjarohttps://facebook.com/manonthemounjaro

In an era of popular weight loss drugs, including GLP-1 agonists like Ozempic (semaglutide), Victoza (liraglutide), Wegovy, and Saxenda, many people are looking for safer, natural alternatives. Calocurb (use code BEN10 to save 10%) is a patented natural plant-based supplement clinically proven to reduce hunger by 30%, cravings by 40%, and calorie intake by an average of 18% — in just an hour. It does this by stimulating the body's own "feel full" hunger hormones cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY). In this episode, Dr. Edward Walker, a scientist and lecturer who helped develop Calocurb, will introduce you to the concept of the "bitter break" and the powerful plant extract, Amarasate, which has shown remarkable results in stimulating anti-appetite hormones when delivered to the small intestine. You'll also get to explore the science behind how this extract works, its impact on glucose and insulin levels, and much more! Over the last 13 years, Dr. Walker's primary research focus has been the investigation of plant-based appetite suppressants that may reduce hunger and support healthy food choices. This work led to the development of Amarasate, a novel New Zealand hops-based appetite suppressant that shares an overlapping mode of action with a new class of effective GLP-1-based anti-obesity drugs. He is passionate about plant-based nutraceuticals and believes that with the appropriate scientific research, they have the potential to improve health and wellness, and even prevent or delay the development of chronic disease. Whether you're interested in nutrition, weight management, or cutting-edge health science, this episode is packed with insights you won't want to miss. Tune in and discover how you can take control of your cravings and support your journey to better health! Full Show Notes: BenGreenfieldLife.com/hungerpodcast Episode Sponsors: BioStack Labs: Get 15% off your purchase of $100 or more by going to biostack.com/ben15. Kineon: Visit shop.kineon.io/bengreenfield today and receive 10% off your purchase. Organifi Happy Drops: Go to organifi.com/Ben for 20% off your order. Mito Red Light: Go to mitoredlight.com and use code BGLIFE to save 5%. Power Plate: Visit PowerPlate.com/ben and save up to $699 today.See omnystudio.com/listener for privacy information.

En France, la prévalence de l'obésité a doublé depuis 1997. Selon les derniers chiffres de la Haute autorité de santé, 17% des adultes et 4% des enfants et adolescents de 6 à 17 ans en souffrent aujourd'hui.Une étape importante a été franchie dans sa prise en charge. Deux médicaments, le liraglutide -nom commercial : Saxenda et le sémaglutide ou Wegovy, initialement connus pour soigner le diabète de type 2, se sont révélés capables de réduire le poids des personnes atteintes d'obésité. Un résultat sans précédent. Sans équivalent, ils font les gros titres des journaux dans le monde entier et affolent les réseaux sociaux.Mais d'abord, comment agissent ces nouveaux médicaments amaigrissants ? Sont-ils aussi efficaces qu'on le dit ? Changent-ils à ce point la donne ? Et révolutionnent-ils vraiment le traitement de l'obésité ?Pour répondre à toutes ces questions, Aline Perraudin, directrice de la rédaction de Santé magazine, échange avec la Pr Judith Aron-Wisnewsky, professeure de nutrition, chercheuse et médecin à l'hôpital de la pitié Salpêtrière à Paris. Spécialiste de l'obésité complexe et des maladies cardiovasculaires qui lui sont associées, la Pr Aron-Wisnewsky est présidente du groupement de coordination et concertation des centres spécialisés obésité.CRÉDITSHypercondriaque est un podcast de Santé magazine animé par Aline PerraudinRédaction et réalisation : Nathalie Courret, Nicolas Jean et Aline PerraudinExtraits : FR3 -18.30 - 14/02/23 ; Franceinfo - 01/07/21 ; TF1 - 10/05/23 ; BFMTV -07/03/24 ; Europe1 - 22/12/14Musique : François ClosIdentité graphique : Upian Communication : Suzanne Méthé, Marianne MeynielMise en ligne : 7 juin 2024Enregistrements : 27 mai et 6 juin 2024 Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

A class of medications known as GLP-1 receptor agonists has revolutionized the treatment of type 2 diabetes and obesity. These drugs mimic the action of glucagon-like peptide-1 (GLP-1), a hormone that stimulates insulin secretion and inhibits glucagon release, helping to regulate blood sugar levels and promote weight loss. In this podcast, we'll talk about the differences among some of the most well-known GLP-1 receptor agonists for type 2 diabetes. Ozempic (Semaglutide) Form: Injectable Dosing Frequency: Once weekly Uses: Primarily for type 2 diabetes (lower blood sugar and A1c); also approved for reducing the risk of major cardiovascular events like heart attack and stroke in adults with type 2 diabetes and known heart disease. Keep in mind, Wegovy (semaglutide) is a higher-dose version that's approved for weight loss. When you start taking Wegovy or Ozempic, you'll begin with a low dosage. Your prescriber will increase your dosage every four weeks until you reach the target amount. However, the specific dosage you inject will differ depending on the medication. The maximum dose for Ozempic is 2mg weekly, while the target dose for Wegovy is 2.4mg weekly. Rybelsus (Semaglutide) Form: Oral tablet Dosing Frequency: Once daily Uses: Lower blood sugar and A1c in people with type 2 diabetes. Rybelsus shares the same active ingredient as the injectable medications Ozempic and Wegovy. Ozempic is also approved for Type 2 diabetes, while Wegovy is approved specifically for weight loss. Rybelsus is available in three different strengths: 3 mg, 7 mg, and 14 mg. Similar to Ozempic, the dose is slowly increased every 4 weeks.  Good to know: It's important to take Rybelsus first thing in the morning with 4 oz of water. After taking it, you should wait at least 30 minutes before eating, drinking, or taking other medications. Failing to do so may reduce its effectiveness. Currently, Rybelsus is undergoing clinical trials to evaluate its effectiveness for weight loss. The trials involve higher doses than those approved for diabetes treatment. Results indicate that a 50 mg dose of oral semaglutide (Rybelsus) achieves weight loss comparable to Wegovy.  Trulicity (Dulaglutide) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes; and like Ozempic, it's also approved for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Like Ozempic and Rybelsus, you will start at a low dose to help reduce side effects. Your healthcare provider will then gradually increase the dose, balancing the management of side effects with the benefits of blood sugar control. The maximum dose for Trulicity is 4.5mg weekly. Victoza (Liraglutide) Form: Injectable Dosing Frequency: Once daily Uses: Type 2 diabetes; also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Victoza is one of three GLP-1 agonists approved for treating Type 2 diabetes in children aged 10 and older. The other options are Trulicity (dulaglutide) and Bydureon BCise (exenatide). More on this later. Ozempic, however, is only approved for use in adults. Saxenda and Victoza are both injectable medications containing liraglutide, but they are approved for different uses. Saxenda is FDA-approved for chronic weight management in people 12 and older, while Victoza is approved for treating Type 2 diabetes in people 10 and older. Victoza also helps lower the risk of major adverse cardiovascular events in adults with diabetes and heart disease. Both medications are injected once a day, starting with a low dose that is gradually increased over time. The target dose for Saxenda is 3 mg once daily, whereas the maximum dose for Victoza is 1.8 mg once daily. Byetta (Exenatide) Form: Injectable Dosing Frequency: Twice daily Uses: Type 2 diabetes. Additional Benefits: It has a shorter duration of action than other GLP-1 agonists, which may be preferable for some patients. Byetta, approved in 2005, was the first GLP-1 medication of its kind for diabetes. Its active ingredient, exenatide, is a synthetic version of a substance found in Gila monster saliva.  The recommended starting dose for Byetta is 5 mcg twice daily, administered within 60 minutes before your morning and evening meals. After one month, your healthcare provider may increase the dose to 10 mcg twice daily. Starting at a lower dose helps reduce stomach-related side effects. Bydureon BCise (Exenatide Extended-Release) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes. Additional Benefits: Extended-release formulation provides a more convenient dosing schedule compared to Byetta. Unlike Byetta, Bydureon BCise has a fixed dose of 2 mg administered once weekly, on the same day each week. It can be taken at any time of day, with or without food. Mounjaro (Tirzepatide) Form: Injectable Dosing Frequency: Once weekly Uses: Type 2 diabetes. Additional Benefits: Dual action as it targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, potentially offering enhanced efficacy in blood sugar control. Mounjaro is not approved for weight loss; however, its active ingredient, tirzepatide, is approved for weight loss under the brand name Zepbound. Typically, Mounjaro's starting dose is 2.5 mg once weekly for four weeks. By week 5, the dosage is often increased to 5 mg once weekly for another four weeks. Following week 9, if necessary for better blood sugar management, the dosage can be escalated to 7.5 mg weekly. It's important not to increase Mounjaro doses by more than 2.5 mg every four weeks. The maximum recommended dosage is 15 mg once weekly. Unlike Ozempic, Trulicity, or Victoza, Mounjaro is currently not approved for any heart-related uses. However, an ongoing clinical trial is assessing its effectiveness in reducing major adverse cardiovascular events in people with Type 2 diabetes. The study is anticipated to conclude in October 2024. Key Differences and Considerations The right GLP-1 agonist for you will likely come down to a few key factors like age, treatment goals, and underlying health conditions. Personal preferences like dosage frequency will also come into play. Dosing Frequency: Once weekly: Ozempic, Trulicity, Bydureon BCise, Mounjaro. Once daily: Rybelsus (oral), Victoza, Saxenda. Twice daily: Byetta. Administration Form: Injectable: All except Rybelsus (oral). Oral: Rybelsus. Indications: Type 2 Diabetes: All medications. Cardiovascular Benefits: Proven cardiovascular benefits: Ozempic, Trulicity, Victoza. Pediatric Use: Approved for children: Victoza (for children 10 years and older). Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market. 

Ozempic, Saxenda, Wegovy, Mounjaro: er zijn steeds meer middelen op de markt die supereffectief zijn tegen overgewicht. Maar hoe is het om zo'n medicijn te gebruiken? Val je daadwerkelijk kilo's af? Freelance journalist Robert Vuijsje prikt dagelijks Saxenda, het zusje van Ozempic, en schrijft daar openhartige columns over in het Volkskrant Magazine. Wat zijn Vuijsje's ervaringen met dit antihongermedicijn? En wat doet hij nog meer om af te vallen? Host Esma Linnemann gaat hierover met hem in gesprek. Host: Esma LinnemannMontage: Tiemen HagemanEindredactie: Corinne van Duin, Pim Huberts, Julia van Alem en Nathalie DenieArtwork: Sophia TwigtSee omnystudio.com/listener for privacy information.

If you are considering or starting a GLP1 Medication for chronic weight management (eg. Ozempic, Wegovy, Mounjaro, Saxenda or Zepbound), then I want to offer some tips to increase your success using these medical treatments! This episode is for educational purposes only – you must speak with your own healthcare provider for individual health advice. I cover appropriate usage of GLP1 meds, titration suggestions to minimize side effects, as well as nutrition & lifestyle considerations. This week's show brought to you by FRIDAY'S HEALTH. If you're in the USA looking for a healthcare provider and comprehensive obesity medicine program to support you in a science-backed, compassionate way, then check out Fridays Health. Each patient works with a medical provider as well as a team of coaches to pair medical treatment with effective behavioural support. Use code HIGH to get $20 USD off the first month of your membership. https://www.joinfridays.com/ FOLLOW SASHA Instagram - https://www.instagram.com/sashahighmd/ Tiktok - https://www.tiktok.com/@sashahighmd WORK WITH ME Join my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweight Recover Strong for Binge Eating - https://www.sashahighmd.com/bed Ontario OHIP-covered Obesity Medicine https://www.highmetabolicclinic.com

In this thought-provoking episode of TLS Podcast, Nio Nyx stirs up a controversial discussion: Is using weight loss drugs like Ozempic and Wegovy cheating? Dive deep into the ethics and implications of medical shortcuts for shedding pounds. With Gianni Storm and Rob B adding their insightful perspectives, this episode is a must-listen for anyone curious about the shortcuts in our health routines. Is this truth, lies, or shenanigans? Join the debate!Support the Show.PODZnetwork.com TLSShow.com

Join me with Dr. Damon McCune as we dive into the hot topic of Ozempic and its impact on the world of weight management. We explore not just Ozempic, but other groundbreaking weight loss drugs, discussing their potential, efficacy, and what bariatric patients specifically need to consider. Tune in to uncover the latest advancements in medical treatments for obesity and learn how these innovations can be part of a comprehensive approach to health and weight loss. Need Support ? www.theritelife.com support@theritelife.com

#906 Wegovy funciona contra obesidade? | Ozempic, Saxenda ou Wegovy: qual é melhor?

Ozempic, Mounjaro, Saxenda e outras novas drogas para emagrecimento estão se tornando cada vez mais populares e sendo divulgadas como seguras e efetivas. Neste vídeo, eu trago dados e fatos sobre estes medicamentos que não muita gente sabe como efeitos colaterais, perda esperada de peso, tempo para perda de peso, efeito sanfona, etc. No final, você poderá decidir se estes medicamentos para emagrecimento são uma boa opção para você ou não. Forte abraço, Rodrigo  

Episode 20 of The Pound of Cure Weight Loss podcast is titled, Here Wegovy: Medicare Coverage for Heart Disease. We called it that because of the NPR article we cover in our In the News segment which states that Medicare will now cover Wegovy for patients who are overweight and suffer from heart disease. How does this impact the future of GLP-1 medications? Tune in to find out.  In our Patient Story, we talk to Larry. He came to us after receiving a high blood pressure diagnosis from his primary care physician. He didn't want to take medication for the rest of his life so he decided to embrace a gastric bypass and has surpassed our expectations of weight loss by combining the surgical tool with weight training. It's a truly inspiring story.  In our Nutrition segment, Zoe offers her #1 tip for grocery shopping that will encourage you to be successful in your weight loss efforts.   Our Economics of Obesity segment covers the GLP-1 shortage. Mounjaro, Wegovy, Zepbound, Saxenda, Trulicity, and Ozempic are on the shortage list. So we are offering some creative solutions to get you through.   Finally, we answer 3 of our listener's questions including, fluid choices for energy and hydration, whether or not revision surgery causes the same amount of weight loss as the initial surgery, and exercise recommendations after weight loss surgery. If you have a question that you'd like for us to answer on the podcast, please reach out to us through social media (Instagram, Tik Tok, Facebook or YouTube), or the website.

Os análogos do GLP-1 – muito conhecidos por nomes comerciais tais como Ozempic e Saxenda revolucionaram o tratamento da obesidade. Pela primeira vez, temos drogas seguras e realmente eficazes no emagrecimento. Mas, como o remédio perfeito não existe, nem tudo são flores. Esses medicamentos possuem efeitos colaterais que incluem azia, refluxo, constipação, diarreia e má digestão. E outro grande problema é o preço: o tratamento típico custa em torno de 1000 reais por mês. Área de membros do blog Ciência Low-Carb: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Clique Aqui!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Estamos no Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. Souto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sari Fontana⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Para ser avisado sobre cada novo episódio e receber os links das matérias mencionadas e as referências bibliográficas por e-mail, cadastre-se gratuitamente em ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drsouto.com.br/podcast ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira seu livro - UMA DIETA ALÉM DA MODA:  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (também na versão Kindle)

El tratamiento dietético para una persona con esos hábitos y objetivos de pérdida de peso debe centrarse en cambios graduales pero sostenibles que puedan integrarse a largo plazo. Aquí te detallo un enfoque paso a paso:1. Establecer un patrón de comidas regularObjetivo: Evitar el picoteo constante y crear una estructura de comidas principales y, si es necesario, meriendas saludables.Estrategia: Planificar tres comidas principales al día y permitir hasta dos meriendas saludables si hay necesidad de comer entre horas.2. Reducir el consumo de ultraprocesadosObjetivo: Disminuir la ingesta de alimentos altos en calorías, grasas saturadas, azúcares añadidos y sal.Estrategia: Reemplazar gradualmente los ultraprocesados por alimentos enteros y naturales. Por ejemplo, cambiar snacks como papas fritas por opciones como frutas, verduras crudas con hummus, o un puñado de frutos secos.3. Aumentar la ingesta de frutas y verdurasObjetivo: Mejorar la saciedad y el aporte de nutrientes con bajo contenido calórico.Estrategia: Incorporar al menos una porción de verduras en cada comida principal y usar frutas como opciones de merienda.4. Controlar las porcionesObjetivo: Reducir el tamaño de las porciones para disminuir la ingesta calórica sin eliminar grupos de alimentos.Estrategia: Usar platos más pequeños, leer las etiquetas para entender las porciones y medir las porciones usando utensilios de cocina o una balanza de alimentos.5. Mejorar la calidad del sueñoObjetivo: La falta de sueño puede aumentar el apetito y disminuir la motivación para el ejercicio.Estrategia: Establecer una rutina de sueño regular, limitar la exposición a pantallas antes de dormir, y crear un ambiente propicio para el sueño.6. Incorporar actividad física gradualmenteObjetivo: Aumentar el gasto energético y mejorar la salud general.Estrategia: Comenzar con actividades de baja intensidad, como caminatas cortas, e ir incrementando la duración e intensidad gradualmente. Buscar formas de estar activo durante las sesiones de videojuegos, como ponerse de pie o utilizar equipos de ejercicio como bicicletas estáticas.7. Educación nutricionalObjetivo: Entender los principios de una alimentación saludable y cómo implementarlos.Estrategia: Considerar la ayuda de un dietista-nutricionista que pueda proporcionar educación nutricional personalizada y ajustar el plan de alimentación a las necesidades, preferencias y estilo de vida del individuo.Es importante recordar que la pérdida de peso y el cambio de hábitos son procesos graduales y requieren compromiso a largo plazo. El apoyo de profesionales de la salud, amigos y familiares puede ser crucial para mantener la motivación y lograr los objetivos establecidos.Justificación del uso de liraglutida: En este escenario, la liraglutida (en una dosis aprobada para el tratamiento de la obesidad) puede justificarse debido a su efecto en la reducción del apetito y la promoción de la saciedad, lo cual puede facilitar una disminución significativa en la ingesta calórica y resultar en pérdida de peso. La pérdida de peso puede, a su vez, ayudar a mejorar las comorbilidades relacionadas con el peso, como la hipertensión y la dislipidemia, y reducir el riesgo de desarrollar diabetes tipo 2.

If you're on a GLP1 medication or considering starting one, this episode is for you. Along with my guest, registered Dietitian Julie Mai, we cover nutrition strategies to minimize GLP1 medication side effects. Julie provides a framework and practical tips to minimize the common side effects of heartburn, nausea and constipation. She shares what foods to avoid and when, along with tips to make the journey of starting your medication much easier! GLP1 medications are a class of medications commonly taken for Type 2 Diabetes and Obesity (medical weight loss). These medications include Saxenda, Ozempic, Mounjaro, Wegovy, Zepbound, Trulicity and others. If you are in Ontario, Nova Scotia or New Brunswick and looking to work with a Registered Dietitian who has extensive experience in the field of obesity, GLP1s, emotional eating or metabolic health, you can book a consultation here: www.highmetabolicclinic.com/nutrition FOLLOW Instagram - https://www.instagram.com/sashahighmd Tiktok - https://www.tiktok.com/@sashahighmd WORK WITH ME Best Weight for Women - https://www.sashahighmd.com/bestweight Recover Strong for Binge Eating - https://www.sashahighmd.com/bed

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog That is a strong statement, however I am confident in saying that belly fat can put you at risk for Alzheimer's disease, because it is a fact supported by medical research. These studies reveal that obesity, especially abdominal obesity (Beer belly, Gut, “Dunlap's disease”…..), increases the onset and rate of Alzheimer's dementia! Another reason to change your lifestyle to benefit your longevity. Abdominal obesity can come from fat accumulation right underneath your skin (the fat you can pinch between 2 fingers) OR the fat that grows inside your abdomen like an apron draped over the intestines. It is called “visceral fat”, and this type of fat is what places you in the crosshairs for several diseases of aging including Alzheimer's Disease, heart disease, stroke, diabetes, and rapid aging.  A large belly is more common in men, but it is still a risk for women if they develop an apple shaped body. Below is a picture of visceral fat, and a diagram of what it looks like in an artist's sketch of a normal weight person. When the yellow fat doubles and triples in thickness the abdomen pushes out to look like a “beer belly”.   Visceral fat extends from your stomach over the transverse colon and your small intestines like an apron.  This fat pad thickens with alcohol abuse (beer belly), high carbohydrate diet, overeating, junk food, under exercise and creates a large pad of fat that secretes inflammatory cells.  The resulting inflammation is the vehicle that damages your brain leading to Alzheimer's disease and damages your arteries leading to heart disease and stroke. In my office we use INBODY machines that measure your Visceral fat, BMI, and percent body fat.  Normal visceral fat is below #10 on our machine, BMI less than or equal to 25, and fat % for men < 19% and for women < 26%. The Research: A recent study correlated the size of patient's belly (visceral belly fat), and obesity with the amount of amyloid plaque (the cause of Alzheimer's disease) in their brain. This was measured by MRI in the study subjects' brains.  The age of the patients studied was between 40-60. The study found that the amount of visceral fat (fat inside your abdomen) is directly correlated with the amount of amyloid plaque and inflammation in the brain!  That causes Alzheimer's Disease. If that doesn't motivate you to lose your belly fat, then you are making a choice to eventually suffer from Alzheimer's disease, a heart attack, a stroke or arthritis.  If you are thinking that you will just wait for “something to happen”, then not making a decision to change your lifestyle is making a decision to take on illness in the future. We have new medications to help you lose that belly fat and they really work. You should ask your doctor to help you and if they don't understand the importance of arriving at ideal weight then look for a different doctor who will help you. Even with medication you will have to put in the work and self-control to turn down unhealthy foods when others are being unhealthy.  You will also have to add daily exercise to your schedule if you really want to avoid Alzheimer's Disease, heart attack, stroke and early death. The possible meds and habits that can help you lose your “belly”: ·     Limit calories and or carbohydrates ·     Increase daily exercise ·     Diet pills (amphetamines that older patients usually can't take) ·     Xenical (Orlistat)-Side effect is fatty diarrhea ·     Qsymia (topiramate/Phentermine) can increase BP ·     Contrave for craving (naltrexone/bupropion) can decrease sex-drive ·     Semelanotide (Imcivree-new), darkens the skin, expensive ·     Metformin ER an oral, effective medication to treat insulin resistance, and promote weight-loss ·     Victoza and Saxenda injections are diabetic treatments, that can cause GI reflux, however they work well for patients who have Type II Diabetes who need to lose weight. Even though many patients lost weight with these medications, many could not tolerate the drugs listed above because of the side effects.  These side effects limited our ability to help all patients lose weight…until now! Now, for the first time we have an effective way to help most people lose their dangerous visceral (belly fat). If you have a big belly you are at high risk for inflammatory diseases like Alzheimer's dementia, obesity, heart disease, diabetes, cancer and stroke. The new weight loss drug's generic name is Semaglutide, and has been marketed under several names: Wegovy, Ozempic, and Rybelsus. A second generic drug that is in the same family of drugs is called Tirzepetide, includes Mounjaro (for diabetics) and Zepbound (for weight loss). All of these drug's work for weight loss, pre-diabetes and Type 2 Diabetes.  Most insurance companies do not cover weight loss and they require a precertification for you to get the medication covered by insurance.  This precertification process is time consuming for the doctor and her staff, which costs the doctor an increase in her overhead to employ a nurse to provide this service for the patient. In general people with a BMI under 30 will not be covered for Semaglutide or Tirzapeptide, however if their BMI is over 30, there is a chance insurance will pay for one of these drugs for a period of time. The market price at the pharmacy is between $900/$1200 per month if you pay out of pocket to your pharmacy. Because of this fact and because we have so many patients whose pellets are not paid for by insurance, we provide access to the generic form of these drugs through a compounding pharmacy. The cost is a fraction of the normal out of pocket cost, about $560 for 3 months supply. In this way we have been able to treat many people who cannot afford to pay the exorbitant going rate for this medication. Because it is costly for a patient to receive the medication no matter how they are able to get it, It is very important for weight loss patients to be compliant and follow a low carbohydrate diet, exercise daily and to refrain from alcohol consumption while they are taking weight loss medications.  We require our patients who request these drugs to be seen at least every 2 months by one of our NPs or our weight loss specialist to help them get the best results possible. These drugs work for weight loss and diabetes by multitasking.  The ways the medication actually works are listed below: Semaglutide and Terzapeptide, ·      decrease hunger between meals   ·     you feel full faster than normal so you eat less ·     decrease sugar and alcohol-craving ·     decrease the release of sugar from the liver when you are fasting, which turns into fat ·     Prevent hypoglycemia which causes hunger and fat gain ·     Makes patients more insulin sensitive. Obesity is not just a lifestyle problem; it is a disease that should be treated with medicine PLUS lifestyle changes. These drug actions take place in the brain, stomach hormones, pancreas and liver, as well as in all the cells in your body. At Bio Balance Health® have years of experience in treating patients with bio-identical testosterone pellets and we have observed that weight loss plus testosterone pellets for patients over 40 allows patients to lose fat without losing muscle. Now we add these weight loss medications to T pellets, and we have the perfect combo for safe weight-loss (really fat loss). The biggest worry for patients is that they may not be able to get off this drug after they achieve ideal weight.  I have found that the longer you have been overweight and the more overweight you are, the higher the risk of needing maintenance medications to maintain your ideal weight. We try to wean our patients off injectable meds by switching them to Metformin ER, a drug that insurance will pay for. With these effective meds we finally, we have an effective preventive treatment to add to our testosterone and estradiol pellets for those people who view Alzheimer's as their worst nightmare, and for those patients who are worried about heart disease, diabetes and stroke  we can prevent the diseases that can ruin our “golden years”.   KCM Research: People with large amounts of visceral fat as they age may have higher risk of Alzheimer's disease. NBC News (11/20, Carroll) reports, “People who have large amounts of” visceral fat “as they age may be at higher risk of developing Alzheimer's disease, a new study suggests.” The findings were presented at the Radiological Society of North America's annual meeting. HealthDay (11/20, Thompson) reports that investigators “compared brain scans of 54 people between the ages of 40 and 60 with their levels of belly fat, BMI, obesity and insulin resistance.” The investigators “found that people who had more visceral fat compared with fat found just under their skin tended to have higher amyloid levels in the precuneus cortex.” The “relationship was worse in men than in women, and higher visceral fat measurements also were related to increased inflammation in the brain.”

Today On Medical Grounds, we will be speaking with Dr. Heather Whitley. Dr. Whitley is a clinical professor in the Department of Pharmacy Practice at the Auburn University Harrison College of Pharmacy. She is a board certified pharmacotherapy specialist and a certified diabetes educator. Earlier this year, Dr. Whitley spoke with us about screening for diabetes in high-risk individuals. Today, she is back to talk about some new things going on in the diabetes and pharmacy world. This is part 1 of a two part series. In Part 1, Dr. Whitley will be discussing shortages in GLP-1 agonist drugs for diabetes and what pharmacists can do to address those shortages.Dr. Whitley recently published a paper in Clinical Diabetes about this topic:Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages(00:09) Introduction to Dr. Whitley(01:08) Publication on strategies for GLP-1 and GLP-1/GIP shortages(02:36) GLP-1 and GLP-1/GIP agonists, names, and dosing(04:15) Why are there shortages?(08:52) Alternatives(10:11) What happens if a patient misses a dose?(12:19) Re-initiation of medications(14:51) GLP-1 agonist equivalency(15:31) Substituting SGLT2s(17:16) Self-sourcing or online sourcing problems(21:51) Managing patient expectations and concernsVisit us at OnMedicalGrounds.com for more podcasts! You can subscribe through your podcast platform, our website, or follow us on social media for podcast updates and medical news. Some of our podcasts offer FREE CME/CE credits.LinkTreeTwitterLinkedInInstagram

Weight loss and obesity medicine expert, Dr. Alo, discusses the most recent data on weight loss medications and how to use them properly. Phentermine, Ozempic, Diethylproprion, Wegovy, Semaglutide, Victoza, Saxenda, and more! https://dralo.net/links

GLP-1 agonists are a class of medications that everyone is talking about right now because of their beneficial effects on weight loss. And while they are effective at helping with weight loss, there have been multiple studies that suggest that there is a link between their use and the new onset of thyroid cancer. Let's talk about this connection in more detail to see if it is something you should actually worry about. First off, where does this information come from? Studies like this one (https://pubmed.ncbi.nlm.nih.gov/36356111/) suggest that there is indeed a real risk of thyroid cancer with long term use of GLP-1 agonists in diabetes. This study showed that there were about 2,500 new cases of thyroid cancer in a sample size of over 3.7 million. The incidence of thyroid cancer in these patients was small but still real. It's important to note here that correlation does not equal causation but this is just adding to the pile of studies that suggest a link between these medications and thyroid cancer so it's definitely something that should be thought about prior to using them. Given this information, is it still worth taking medications like Wegovy, semaglutide, saxenda, and victoza? In some situations, it may make sense but my recommendation is to always try to lose weight with diet and exercise first. If you are going to use these medications then do your best to use them in the short term for no more than 1 year. This will minimize the negative side effects while maximizing their benefits. My personal recommendation would still be to try other treatments like bioidentical hormone replacement therapy prior to using GLP-1 agonists. #weightloss #glp1 #weight #weightlosstips #obesity #thyroidcancer #thyroid Download my free thyroid resources here (including hypothyroid symptoms checklist, the complete list of thyroid lab tests + optimal ranges, foods you should avoid if you have thyroid disease, and more): https://www.restartmed.com/start-here/ Recommended thyroid supplements to enhance thyroid function: - Supplements that everyone with hypothyroidism needs: https://bit.ly/3tekPej - Supplement bundle to help reverse Hashimoto's: https://bit.ly/3gSY9eJ - Supplements for those without a thyroid and for those after RAI: https://bit.ly/3tb36nZ - Supplements for active hyperthyroidism: https://bit.ly/3t70yHo See ALL of my specialized supplements including protein powders, thyroid supplements, and weight loss products here: https://www.restartmed.com/shop/ Want more from my blog? I have more than 400+ well-researched blog posts on thyroid management, hormone balancing, weight loss, and more. See all blog posts here: https://www.restartmed.com/blog/ Prefer to listen via podcast? Download all of my podcast episodes here: https://apple.co/3kNYTCS Disclaimer: Dr. Westin Childs received his Doctor of Osteopathic Medicine from Rocky Vista University College of Osteopathic medicine in 2013. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Childs is no longer practicing medicine and does not hold an active medical license so he can focus on helping people through videos, blog posts, research, and supplement formulation. To read more about why he is no longer licensed please see this page: https://www.restartmed.com/what-happened-to-my-medical-license/ This video is for general informational, educational, and entertainment purposes only. It should not be used to self-diagnose and it is not a substitute for a medical exam, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Childs and you. You should not make any changes to your medications or health regimens without first consulting a physician. If you have any questions please consult with your current primary care provider. Restart Medical LLC and Dr. Westin Childs are not liable or responsible for any advice, course of treatment, diagnosis, or any other information

Come and join us for our special two-hour, season 1 finale! We will be reminiscing about some of our favorite moments from season 1 and will be joined by Dr. Michael Albert from episode 1 to discuss the future of GLP-1 medications. We'll explore their potential use in treating addiction and sleep apnea and delve into the possibilities of Retatrutide and increased doses of oral Semaglutide. With medications like Ozempic, Wegovy, Mounjaro, Victoza, Saxenda, and Trulicity, the opportunities for improved health are limitless.Dr. Michael Albert, Accomplish Health https://www.accomplish.health/abouthttps://www.tiktok.com/@michaelalbert...https://www.instagram.com/michaelalbe...Explore the podcast on YouTubehttps://www.youtube.com/@theplussidez Support the showKim Carlos @DMFKimonMounjaro on TikTokJernine Trott @TheeJernine on TikTokKat Carter @KatCarter7 on TikTokLydia Roberts @mounjaro_GLP_Help on TikTok

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new insulin pump gets FDA approval, once-weekly basal insulin for type 2 gets through another trial, New Jersey caps insulin prices for some, possible link between ability to chew and glucose control, a landmark diabetes study moves on to aging and T1D, JDRF Children's Congress and more! Learn about Moms' Night Out - a new event for moms of children with diabetes Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by AG1. AG1 helps you build your health, foundation first. XX Our top story, Tandem's Mobi Pump is approved. The FDA cleared the tiny pump for people with diabetes ages six and up. Tandem says mobie is fully controllable from a mobile app and is the world's smallest durable AID system. It still has a button on the pump to dose and holds 200 units. You use the same infusion set as the current Tandem pumps and Mobi uses Control IQ. Limited release planned for late this year and fully available early 2024. https://www.drugdeliverybusiness.com/fda-clears-tandem-mobi-automated-insulin-pump/ XX Learning more about a newly approved therapy for type 1 diabetes called Lantidra. Two safety and efficacy studies found that 21 participants who took Lantidra did not need to administer themselves insulin for a year or more. Twelve of those participants did not need to take insulin for up to 5 years, and 9 did not need insulin for over 5 years. Lantidra is an allogeneic (donor) pancreatic islet cellular therapy. In other words, Lantidra uses cells taken — or isolated — from human organ donor pancreases. “In [a] subsequent process, the insulin-producing islets are purified from the rest of the pancreatic tissue using a density gradient. Once the islets are isolated, purified, and put for a short time in cell culture, the cell preparation is infused into the liver of the recipient,” he explained. https://www.medicalnewstoday.com/articles/fda-approves-first-cellular-therapy-for-type-1-diabetes-what-does-it-do#How-does-islet-cellular-therapy-work? XX Once weekly basal insulin for type 2 gets through another trial. After 26 weeks of treatment and five weeks of follow-up, patients on weekly insulin icodec had significantly larger improvements in their HbA1C than those using daily insulin. Both groups had an extremely low rate of adverse events. These researches say next step is FDA evaluation. https://www.utsouthwestern.edu/newsroom/articles/year-2023/july-weekly-insulin-found-safe.html XX That's the idea behind Fractyl Health's treatment for type 2 diabetes—which could also be used for weight control. The Lexington, Massachusetts-based biotech company is in the early stages of developing a one-time gene therapy intended to lower blood sugar and body weight using the same mechanism as semaglutide. “You have this problem where you need to stay on therapy for efficacy,” says Harith Rajagopalan, a cardiologist by training and CEO and cofounder of Fractyl Health. “That's the Achilles heel.” The company wants to deliver an artificial gene to the pancreas that continuously produces the GLP-1 hormone so there's no need for weekly injections. The approach, called gene therapy, uses inactivated viruses to carry a therapeutic gene to pancreatic cells. (Viruses are used because of their natural ability to deliver genetic material to cells.) The company is aiming to begin an initial human trial by the end of 2024 https://www.wired.com/story/a-one-time-shot-for-type-2-diabetes-a-biotech-company-is-on-it/ XX Gov. Phil Murphy signed three bills into law Monday aimed at cutting the high cost of prescription drugs in New Jersey. The new laws will cap how much residents will pay for some popular medications such as insulin, prevent pharmacy benefit managers from engaging in practices that make drugs more expensive, and create a panel that will monitor prices set by pharmaceutical companies. One measure (S1614) would cap the cost of insulin, epinephrine auto-injector devices and asthma inhalers for state and local public workers enrolled in the State Health Benefits Program, the School Employees' Health Benefits Program and other state-regulated plans. For a 30-day supply, insulin will cost $35, EpiPens $25 and asthma inhalers would be capped at $50, according to the bill. The law takes effect next year. https://www.nj.com/politics/2023/07/new-laws-to-stem-high-cost-of-prescription-drugs-in-nj-were-just-signed-by-gov-murphy.html XX The European Medicines Agency (EMA) said on Tuesday it has extended its probe into Novo Nordisk's (NOVOb.CO) diabetes drugs Ozempic and weight-loss treatment Saxenda, following two reports of suicidal thoughts, to include other drugs in the same class. The agency began its review on July 3 after Iceland's health regulator flagged the reports of patients thinking about suicide and one case of thoughts of self harm after use of Novo's drugs. https://www.reuters.com/business/healthcare-pharmaceuticals/eu-extends-ozempic-probe-include-other-drugs-2023-07-11/ XX We often hear that diabetes can lead to problems with your teeth.. but one researcher says it might be the other way around. A University at Buffalo researchers says there is a notable correlation between chewing functionality and blood glucose levels in people with type 2. Specifically, he found that patients with T2D who maintain a full chewing ability exhibit significantly lower blood glucose levels compared to those with compromised chewing function. The thinking here is that chewing stimulates the body in all sorts of ways, including releasing hormones that help you feel fuller and help in digestion. More studies are expected. DOI: 10.1371/journal.pone.0284319 https://scitechdaily.com/the-surprising-connection-between-chewing-and-type-2-diabetes/ XX The next step of the landmark Diabetes Control and Complications Trial will focus on aging with type 1 diabetes. The original randomized DCCT clinical trial results, published September 30, 1993, in the New England Journal of Medicine, proved that early intensive glycemic control was the key to preventing or slowing the progression of long-term eye, kidney, and nerve complications of type 1 diabetes. Subsequently, EDIC has yielded many more major findings including that early tight glycemic control also reduces cardiovascular risk and prolongs survival in type 1 diabetes. subsequent EDIC data also have suggested that it is never too late to initiate intensive glycemic control Together, DCCT and EDIC — both funded by the National Institutes of Health at 27 sites in the United States and Canada — have changed the standard of care for people with type 1 diabetes Prior to the DCCT, between 1930 and 1970, about a third of people with type 1 diabetes developed vision loss and one in five experienced kidney failure and/or myocardial infarction. Stroke and amputation were also common, DCCT/EDIC chair David M. Nathan, MD, said while introducing the symposium. "All of the advances in care of type 1 diabetes have developed because this study demonstrated that it was important — continuous glucose monitoring (CGM), new insulins, better [insulin] pumps…I think the most profound finding is that mortality in our intensively treated cohort is the same as in the general population. That says it all," Nathan told Medscape Medical News. https://www.medscape.com/viewarticle/994221 XX Commercial – AG1 XX Today, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, urged members of the Senate Appropriations Committee to renew the Special Diabetes Program (SDP) and support policies to ensure insulin is available at an affordable and predictable price. Opened by U.S. Senator Patty Murray (D-WA) and led by U.S. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), the hearing took place during the 2023 JDRF Children's Congress, a biennial event that brings over 160 kids and teens living with T1D face-to-face with lawmakers and top decision-makers. The youth delegates traveled to Washington, D.C. from across the country and JDRF's international affiliates in the United Kingdom, Australia, the Netherlands, and Canada. The SDP has accelerated the pace of T1D research through a long-term investment of funding at the National Institutes of Health. The program has led to significant scientific breakthroughs, including Tzield, the first disease-modifying treatment for T1D, which can delay the onset of the disease by over two years. Without Congressional action, the SDP will expire at the end of September. "The Special Diabetes Program has fundamentally changed what it means to live with diabetes, put new life-changing therapies in our hands, and brought us closer to cures," said Aaron Kowalski, Ph.D., JDRF CEO. "We must keep this momentum going so we can capitalize on the progress to date and realize cures. However, until we have cures, people need access to affordable insulin. JDRF urges Congress to pass the bipartisan INSULIN Act of 2023, which will establish a $35 per month insulin copay cap for people with commercial insurance and includes other provisions that would make insulin more affordable for everyone, regardless of insurance status." Dr. Kowalski was joined at the hearing by Dr. Griffin Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, who provided testimony on the scientific value of the SDP, and Jimmy Jam, award-winning producer, songwriter, musician, member of the Rock & Roll Hall of Fame, and T1D parent. "My son Max, who is now in his twenties, was just two years old when he was first diagnosed with type 1 diabetes. Late nights working on music became late nights working on music and waking up my son to test and manage his blood sugar levels," said Jimmy Jam. "Type 1 diabetes should be one of those things we can all agree on. Diabetes doesn't care if you're a Democrat or a Republican. We can all agree that there should be research to improve the lives of those with diabetes. We can all agree that insulin should be affordable for all who need it." Two 2023 JDRF Children's Congress delegates shared their T1D experience with the committee: Maria Muayad: 10-year-old Maria is from Maine and is a member of her school's civil rights club and math challenge group. Every November, Maria, and her mother, Golsin, give blue ribbons to the staff at her school in honor of National Diabetes Awareness Month. Elise Cataldo: 15-year-old Elise lives in New Hampshire and is passionate about educating those around her about life with T1D and tries to use things like pump site changes and blood sugar checks as opportunities to help others learn. Following the hearing, the 2023 JDRF Children's Congress delegates continued their advocacy by meeting with lawmakers in their Capitol Hill offices. https://www.prnewswire.com/news-releases/2023-jdrf-childrens-congress-delegates-urge-lawmakers-to-support-type-1-diabetes-research-and-access-to-affordable-insulin-301874927.htmlXX XX A 23-year-old with type 1 diabetes has broken the record for circumnavigating Britain in a kayak after paddling 2,000 miles in 40 days. Dougal Glaisher beat the previous record by 27 days. Glaisher was diagnosed with type 1 diabetes at the age of 19 shortly after winning the Oban Sea Kayak race in Scotland, when he had blurred vision and struggled to recover his energy. The expedition was to raise money for the UK-based charity Action4Diabetes and Glaisher livestreamed his blood sugar On Tuesday he was well stocked with a bunch of bananas and a stash of cereal bars lashed to his boat. But in remote areas it was more challenging. Around the islands off Scotland he ran out of freeze-dried meals and survived on porridge for several days. He also sourced drinking water from streams. . It is the first time anyone has used a surfski – a kayak that you sit on top of – to paddle around the country. XX On the podcast next week.. I sat down with Dexcom's new Chief Commercial officer to talk about their announcements from this week about the type 2 market and other features important to people with type 1. Our last epoisde is all about Kickass Healthy LADA That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.